Pfizer Inc. (NYSE:PFE) Stock Holdings Lessened by UMB Bank n.a.

UMB Bank n.a. trimmed its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 7.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 196,472 shares of the biopharmaceutical company's stock after selling 15,041 shares during the period. UMB Bank n.a.'s holdings in Pfizer were worth $4,979,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in PFE. Rialto Wealth Management LLC bought a new position in Pfizer during the 4th quarter valued at $26,000. Clarity Asset Management Inc. bought a new position in shares of Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC grew its stake in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the fourth quarter worth about $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer in the fourth quarter valued at about $30,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

PFE traded up $0.22 on Wednesday, reaching $24.52. The company had a trading volume of 18,781,501 shares, compared to its average volume of 40,952,537. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a market capitalization of $139.38 billion, a P/E ratio of 17.38, a PEG ratio of 0.64 and a beta of 0.57. The company has a fifty day moving average of $22.93 and a 200-day moving average of $24.98. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.82 earnings per share. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.02%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PFE. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, UBS Group increased their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.